Beinaglutide
- Generic Name
- Beinaglutide
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 123475-27-4
- Unique Ingredient Identifier
- 38I1O6L31D
- Background
Beinaglutide is under investigation in clinical trial NCT03829891 (Study for Beinaglutide Versus Glargine Therapy in Glycemic Variability of Type 2 Diabetes Mellitus).
- Indication
用于成人2型糖尿病患者控制血糖；适用于单用二甲双胍血糖控制不佳的患者。
- Associated Conditions
- -
- Associated Therapies
- -
The Effects of Glucose Control and Weight Loss Between Beinaglutide and Dulaglutide in Type 2 Diabetes With Overweight or Obesity.
- Conditions
- Interventions
- First Posted Date
- 2021-08-13
- Last Posted Date
- 2023-03-17
- Target Recruit Count
- 120
- Registration Number
- NCT05005741
- Locations
- 🇨🇳
The First Affiliated Hospital of Harbin Medical University, Ha'erbin, Heilongjiang, China
🇨🇳The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, Henan, China
🇨🇳The Second Xiangya Hospital of Central South University, Changsha, Hunan, China
Comparing the Efficacy and Safety Between Short-term Continuous Subcutaneous Beinaglutide Injection and Continuous Subcutaneous Insulin Infusion (CSII) for Newly Diagnosed Type 2 Diabetes
- First Posted Date
- 2019-06-17
- Last Posted Date
- 2019-06-17
- Lead Sponsor
- Beijing Hospital
- Target Recruit Count
- 260
- Registration Number
- NCT03987308
- Locations
- 🇨🇳
First Hospital of Peking University, Beijing, China,Beijing, China
🇨🇳Ninth Hospital of the Joint Logistics Support Force of the Chinese People's Liberation Army, Fuzhou, China,Fuzhou, China
🇨🇳Heilongjiang provincial hospital, Harbin, China,Harbin, China
Study for Beinaglutide Versus Glargine Therapy in Glycemic Variability of Type 2 Diabetes Mellitus
- Conditions
- Interventions
- First Posted Date
- 2019-02-04
- Last Posted Date
- 2022-01-19
- Lead Sponsor
- Xijing Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT03829891
- Locations
- 🇨🇳
Chang'an Hospital, Xi'an, China,Shanxi, China
🇨🇳Shaanxi Aerospace Hospital, Xi'an, China,Shanxi, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.